EAU 2021: Association of Local Progression with Deterioration of Urinary Symptoms and Occurrence of Genitourinary Adverse Events (AEs) in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post Hoc Analysis of PROSPER

(UroToday.com) In PROSPER (NCT02003924),¹ a multinational, double-blind, randomized Phase 3 study that examined enzalutamide (ENZA) in men with nmCRPC continuing androgen deprivation therapy, ENZA significantly improved metastasis-free survival versus placebo (PBO).